Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: In the randomized phase 2/3 KEYNOTE-010 study (NCT01905657), pembrolizumab significantly prolonged OS compared with docetaxel in previously treated, PD-L1–positive (tumor proportion score [TPS] ?1% and ?50%), advanced NSCLC. Here, we report HRQoL findings from KEYNOTE-010. Methods: Patients (pts) with PD-L1–positive NSCLC who progressed after platinum-based chemotherapy were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg Q3W or docetaxel 75 mg/kg.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
